Gastric carcinogenesis and underlying molecular mechanisms: Helicobacter pylori and novel targeted therapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Nishizawa, Toshihiro ^a   Suzuki, Hidekazu ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN; CYTIDINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL SECRETION SYSTEM; CAGA PROTEIN, HELICOBACTER PYLORI; DNA; ERBB2 PROTEIN, HUMAN; RNA;

ANGIOGENESIS; CANCER STEM CELL; CARCINOGENESIS; DNA METHYLATION; DRUG TARGETING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; REVIEW; STOMACH CANCER; STOMACH CARCINOMA; STOMACH EPITHELIUM; TUMOR SUPPRESSOR GENE; ANIMAL; BACTERIAL SECRETION SYSTEM; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HELICOBACTER INFECTIONS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROMOTER REGION; STOMACH NEOPLASMS;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL SECRETION SYSTEMS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICRORNAS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RNA, NEOPLASM; STOMACH NEOPLASMS;

EID: 84928557918     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/794378     Document Type: Review

References (51)

1. K. Fukase, M. Kato, S. Kikuchi et al. , "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial, " The Lancet, vol. 372, no. 9636, pp. 392-397, 2008.
2. H. Suzuki, T. Nishizawa, and T. Hibi, "Helicobacter pylori eradication therapy, " Future Microbiology, vol. 5, no. 4, pp. 639-648, 2010.
3. T. Nishizawa, H. Suzuki, I. Nakagawa et al. , "Early Helicobacter pylori eradication restores sonic hedgehog expression in the gastric mucosa of mongolian gerbils, " Digestion, vol. 79, no. 2, pp. 99-108, 2009.
4. M. Ito, S. Takata, M. Tatsugami et al. , "Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review, " Journal of Gastroenterology, vol. 44, no. 5, pp. 365-371, 2009.
5. L. Fuccio, R. M. Zagari, L. H. Eusebi, L. Laterza, V. Cennamo, and L. Ceroni, "Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?" Annals of Internal Medicine, vol. 151, no. 7, pp. 121-128, 2009.
6. M. Asaka, M. Kato, S.-I. Takahashi et al. , "Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition, " Helicobacter, vol. 15, no. 1, pp. 1-20, 2010.
7. H. Suzuki, T. Nishizawa, H. Tsugawa, and T. Hibi, "Molecular approaches and modern clinical strategies for the management of Helicobacter pylori infection in Japan, " Keio Journal of Medicine, vol. 61, no. 4, pp. 109-119, 2012.
8. M. Suzuki, S. Miura, M. Suematsu et al. , "Helicobacter pyloriassociated ammonia production enhances neutrophil-dependent gastric mucosal cell injury, " The American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 263, no. 5, pp. G719-G725, 1992.
9. H. Suzuki, T. Nishizawa, H. Tsugawa, S. Mogami, and T. Hibi, "Roles of oxidative stress in stomach disorders, " Journal of Clinical Biochemistry and Nutrition, vol. 50, no. 1, pp. 35-39, 2012.
10. T. Ishimoto, O. Nagano, T. Yae et al. , "CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc? and thereby promotes tumor growth, " Cancer Cell, vol. 19, no. 3, pp. 387-400, 2011.
11. R. Chaturvedi, M. Asim, M. B. Piazuelo et al. , "Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastric epithelial cells withDNAdamage, " Gastroenterology, vol. 146, no. 7, pp. 1739. e14-1751. e14, 2014.
12. S. Nagini, "Carcinoma of the stomach: a reviewof epidemiology, pathogenesis, molecular genetics and chemoprevention, " World Journal of Gastrointestinal Oncology, vol. 4, no. 7, pp. 156-169, 2012.
13. M. Hatakeyama, "Oncogenic mechanisms of the Helicobacter pylori CagA protein, " Nature Reviews Cancer, vol. 4, no. 9, pp. 688-694, 2004.
14. M. Hatakeyama, "Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis, " Cell Host &Microbe, vol. 15, pp. 306-316, 2014.
15. H. Higashi, R. Tsutsumi, A. Fujita et al. , "Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14428-14433, 2002.
16. H. Tsugawa, H. Suzuki, H. Saya et al. , "Reactive oxygen speciesinduced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells, " Cell Host and Microbe, vol. 12, no. 6, pp. 764-777, 2012.
17. N. Nagata, J. Akiyama, H. Marusawa et al. , "Enhanced expression of activation-induced cytidine deaminase in human gastric mucosa infected by Helicobacter pylori and its decrease following eradication, " Journal of Gastroenterology, vol. 49, no. 3, pp. 427-435, 2014.
18. Y. Matsumoto, H. Marusawa, K. Kinoshita et al. , "Helicobacter pylori infection triggers aberrant expression of activationinduced cytidine deaminase in gastric epithelium, " Nature Medicine, vol. 13, no. 4, pp. 470-476, 2007.
19. T. Shimizu, H. Marusawa, Y. Matsumoto et al. , "Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection, " Gastroenterology, vol. 147, no. 2, pp. 407. e3-417. e3, 2014.
20. W. Yang, A. Raufi, and S. J. Klempner, "Targeted therapy for gastric cancer:molecular pathways and ongoing investigations, " Biochimica et Biophysica Acta, vol. 1846, no. 1, pp. 232-237, 2014.
21. H.-C. Chen, H.-J. Chen, M. A. Khanet al. , "Geneticmutationsof p53 and k-ras in gastric carcinomapatients fromHunan, China, " Tumor Biology, vol. 32, no. 2, pp. 367-373, 2011.
22. T. Hiyama, K. Haruma, Y. Kitadai et al. , "K-ras mutation in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer, " International Journal of Cancer, vol. 97, no. 5, pp. 562-566, 2002.
23. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al. , "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, " The Lancet, vol. 376, no. 9742, pp. 687-697, 2010.
24. F. Lordick, Y.-K. Kang, H.-C. Chung et al. , "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial, " The Lancet Oncology, vol. 14, no. 6, pp. 490-499, 2013.
25. T. Waddell, I. Chau, D. Cunningham et al. , "Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial, " The Lancet Oncology, vol. 14, no. 6, pp. 481-489, 2013.
26. T. Satoh, R. H. Xu, H. C. Chung et al. , "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study, " Journal of Clinical Oncology, vol. 32, pp. 2039-2049, 2014.
27. A. Ohtsu, J. A. Ajani, Y.-X. Bai et al. , "Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study, " Journal of Clinical Oncology, vol. 31, no. 31, pp. 3935-3943, 2013.
28. H. I. Grabsch and P. Tan, "Gastric cancer pathology and underlying molecular mechanisms, " Digestive Surgery, vol. 30, no. 2, pp. 150-158, 2013.
29. A. Horii, S. Nakatsuru, Y. Miyoshi et al. , "The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer, " Cancer Research, vol. 52, no. 11, pp. 3231-3233, 1992.
30. Y.-G. Wen, Q. Wang, C.-Z. Zhou, G.-Q. Qiu, Z.-H. Peng, and H.-M. Tang, "Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway, " Oncology Reports, vol. 24, no. 1, pp. 89-95, 2010.
31. X.-T. Hu and C. He, "Recent progress in the study ofmethylated tumor suppressor genes in gastric cancer, " Chinese Journal of Cancer, vol. 32, no. 1, pp. 31-41, 2013.
32. H.-L. Wang, P.-Y. Zhou, P. Liu, and Y. Zhang, "Role of p16 gene promoter methylation in gastric carcinogenesis: a metaanalysis, " Molecular Biology Reports, vol. 41, no. 7, pp. 4481-4492, 2014.
33. A. S. L. Cheng, M. S. Li, W. Kang et al. , "Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis, " Gastroenterology, vol. 144, no. 1, pp. 122. e9-133. e9, 2013.
34. Y. Hayashi, M. Tsujii, J. Wang et al. , "CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylorirelated carcinogenesis, " Gut, vol. 62, no. 11, pp. 1536-1546, 2013.
35. S. Nanjo, K. Asada, S. Yamashita et al. , "Identification of gastric cancer risk markers that are informative in individualswith past H. pylori infection, " Gastric Cancer, vol. 15, no. 4, pp. 382-388, 2012.
36. T. Niwa, T. Toyoda, T. Tsukamoto, A. Mori, M. Tatematsu, and T. Ushijima, "Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent, " Cancer Prevention Research, vol. 6, no. 4, pp. 263-270, 2013.
37. E. van Cutsem, S. de Haas, Y.-K. Kang et al. , "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial, " Journal of Clinical Oncology, vol. 30, no. 17, pp. 2119-2127, 2012.
38. L. Shen, J. Li, J. Xu et al. , "Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study), " Gastric Cancer, 2014.
39. C. S. Fuchs, J. Tomasek, C. J. Yong et al. , "Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, " The Lancet, vol. 383, no. 9911, pp. 31-39, 2014.
40. J. Li, S. Qin, J. Xu et al. , "Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial, " Journal of Clinical Oncology, vol. 31, no. 26, pp. 3219-3225, 2013.
41. T. Nishizawa and H. Suzuki, "The role of microRNA in gastric malignancy, " International Journal ofMolecular Sciences, vol. 14, no. 5, pp. 9487-9496, 2013.
42. K. Hirata, H. Suzuki, H. Imaeda et al. , "CD44 variant 9 expression in primary early gastric cancer as a predictivemarker for recurrence, " British Journal of Cancer, vol. 109, no. 2, pp. 379-386, 2013.
43. Y.-Y. Ma and H.-Q. Tao, "Microribonucleic acids and gastric cancer, " Cancer Science, vol. 103, no. 4, pp. 620-625, 2012.
44. A. Shiotani, N. Uedo, H. Iishi et al. , "H. pylori eradication did not improve dysregulation of specific oncogenic miRNAs in intestinal metaplastic glands, " Journal of Gastroenterology, vol. 47, no. 9, pp. 988-998, 2012.
45. M. Suzuki, H. Suzuki, Y. Minegishi, K. Ito, T. Nishizawa, and T. Hibi, "H. pylori-eradication therapy increases RUNX3 expression in the glandular epithelial cells in enlarged-fold gastritis, " Journal of Clinical Biochemistry andNutrition, vol. 46, no. 3, pp. 259-264, 2010.
46. K. W. Lai, K. X. Koh, M. Loh et al. , "MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer, " European Journal of Cancer, vol. 46, no. 8, pp. 1456-1463, 2010.
47. M. Wang, C. Li, B. Yu et al. , "Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer, " Journal of Gastroenterology, vol. 48, no. 9, pp. 1023-1033, 2013.
48. R. Suzuki, E. Yamamoto, M. Nojima et al. , "Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk, " Journal of Gastroenterology, vol. 49, no. 7, pp. 1135-1144, 2014.
49. S. Takaishi, T. Okumura, S. Tu et al. , "Identification of gastric cancer stem cells using the cell surface marker CD44, " Stem Cells, vol. 27, no. 5, pp. 1006-1020, 2009.
50. Y. Wakamatsu, N. Sakamoto, H. Z. Oo et al. , "Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer, " Pathology International, vol. 62, no. 2, pp. 112-119, 2012.
51. C. Varon, P. Dubus, F. Mazurier et al. , "Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice, " Gastroenterology, vol. 142, no. 2, pp. 281-291, 2012.